Last reviewed · How we verify
LY900014
LY900014 is a rapid-acting insulin lispro formulation that mimics endogenous insulin by binding to insulin receptors to facilitate glucose uptake and metabolism.
LY900014 is a rapid-acting insulin lispro formulation that mimics endogenous insulin by binding to insulin receptors to facilitate glucose uptake and metabolism. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | LY900014 |
|---|---|
| Also known as | Ultra-Rapid Lispro, Lyumjev |
| Sponsor | Eli Lilly and Company |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
LY900014 is an ultra-rapid insulin lispro developed using Eli Lilly's proprietary formulation technology to accelerate the onset and peak of insulin action compared to standard insulin lispro. It is designed to more closely match the body's natural postprandial insulin secretion pattern, reducing blood glucose excursions after meals in patients with diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
Key clinical trials
- A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India (PHASE4)
- A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes (PHASE1)
- A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) (PHASE3)
- A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes (PHASE3)
- A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes (PHASE2)
- A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes (PHASE3)
- A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes (PHASE3)
- A Study of LY900014 in Healthy Chinese Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY900014 CI brief — competitive landscape report
- LY900014 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI